24-Hour One-Shot Pathogen Detector
UCSF’s automated metagenomic next-generation sequencing technology delivers same-day detection of almost any pathogen
James Strachan | | 4 min read
Credit: The Analytical Scientist
Metagenomic next-generation sequencing (mNGS) technology, developed by University of California – San Francisco researchers, can identify a wide range of disease-causing pathogens in under 24 hours, according to two studies.
A seven-year study published in Nature Medicine evaluated mNGS on nearly 5,000 cerebrospinal fluid (CSF) samples, identifying pathogens in 86 percent of neurological infections – a rate higher than traditional diagnostic methods.
By analyzing all genetic material in a sample, mNGS bypasses the limitations of targeted tests, which focus on specific pathogens. Instead, it sequences the entire pool of DNA and RNA, then uses computational tools to filter out human genetic material, isolating sequences from bacteria, viruses, fungi, or parasites. This method enables rapid identification of unusual or rare pathogens, which traditional methods might miss.
“Our technology is deceptively simple,” said Charles Chiu, professor of laboratory medicine and infectious diseases at UCSF and senior author of the study, in a press release. “By replacing multiple tests with a single test, we can take the lengthy guesswork out of diagnosing and treating infections.”
The Analytical Scientist Presents:
Enjoying our content? Join a growing community of like-minded individuals with the hottest topics at your fingertips, specially curated by our Editorial team.
The second study, published in Nature Communications, showed how mNGS – now automated – works for respiratory infections. This version was able to identify pathogens in respiratory fluid – SARS-CoV-2, influenza A and B, and RSV – in under 24 hours.
"Our goal was to have the entire process completed within 12 to 24 hours, giving a same-day or next-day result," explained Chiu. The test can detect low viral loads and genetically diverse viruses, including new strains.
Both the CSF and respiratory versions of the mNGS test have received breakthrough device designation from the U.S. Food and Drug Administration (FDA).
To commercialize the technology, several of the researchers founded Delve Bio, which is now the exclusive provider of the mNGS CSF test developed at UCSF.
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.
From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
